CytoMed Therapeutics Limited (GDTC) Operating cash flow 2022–2025
CytoMed Therapeutics Limited (GDTC) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$2.9MFY2025 · since FY2022: -$1.0M → -$2.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$2.9M | -45.0% |
| FY2024 | -$2.0M | +23.8% |
| FY2023 | -$2.6M | -149.4% |
| FY2022 | -$1.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More GDTC financial trends
GDTC RevenueGDTC Net incomeGDTC Net marginGDTC Gross profitGDTC Gross marginGDTC Operating incomeGDTC Operating marginGDTC Free cash flowGDTC Capital expendituresGDTC Return on equityGDTC Stock buybacksGDTC Dividends paidGDTC Total assetsGDTC Total liabilitiesGDTC Shareholders’ equityGDTC overview →